Prolonged-release ketamine tablet has potential as affordable and convenient treatment for severe depression and with minimal side effects

AUCKLAND, New Zealand, June 24, 2024. Douglas Pharmaceuticals, New Zealand's largest pharmaceutical company, is pleased to announce that results from...

71% of patients found to experience a relapse compared with 43% who received the pills twice a week

A groundbreaking study led by researchers from Monash University and the Baker Heart and Diabetes Institute has presented compelling evidence on the...

A new pill that releases ketamine slowly over time could treat severe depression without causing the psychedelic side effects often associated with...

TUESDAY, June 25, 2024 -- A new slow-release pill form of ketamine can quell hard-to-treat depression without producing psychedelic side effects...

A device worn on the head, which emits a very low-frequency magnetic field, has improved symptoms in four male patients with major depressive...

Heavy rain and strong winds may cause some problems in northern parts of the Quinte Region. Environment Canada issued a Severe Thunderstorm Watch for...

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South...

Acino gains commercial rights for EXBLIFEP® (cefepime/enmetazobactam) within the member states of the Gulf Cooperation Council (GCC) and South...